J&J Moves Cell Therapy Into Mid-Stage Trials
This article was originally published in Pharmaceutical Approvals Monthly
The big pharma is developing CNTO 2476, human umbilical tissue-derived cells, for the treatment of dry age-related macular degeneration, the form of AMD with no current treatments.
You may also be interested in...
The dual GLP-1/GIP agonist outpaced Novo's blockbuster GLP-1 analogue at all three doses, including the important low dose, on A1C reduction and weight reduction in patients with type 2 diabetes.
The company released an annual pricing report, showing that Sanofi's US average net prices declined for the fifth year in a row.
The firm’s acute migraine treatment Nurtec ODT generated $65m in 2020 after launching a year ago. Biohaven aims for Nurtec to become the leader in what could be a $4bn-$5bn category in the US.